|
⚠️ Professional Use Only This content is intended exclusively for licensed medical professionals. It does not constitute clinical advice. Always follow applicable regulations and guidelines in your jurisdiction. |
|
✍️ Written by: Celmade Editorial Team | AI-Assisted Content 🔬 Medically Reviewed by: Stella Williams, Medical Aesthetic Injector 📅 Published: May 2nd, 2026 | Last Reviewed: May 2nd, 2026 🔗 View Reviewer Full Profile → celmade.co/pages/team-stella-williams |
|
📌 Editorial Note: This article was drafted with AI assistance and reviewed, fact-checked, and approved by Stella Williams, a qualified Medical Aesthetic Injector. All clinical claims are supported by cited references. |
Injectable lipolytics — agents that chemically destroy subcutaneous fat cells — represent one of the most technically specific and outcome-dependent treatments in non-surgical aesthetic medicine. When patient selection is correct, the treatment zone is appropriate, the product and protocol are sound, and the patient's expectations are accurately set, injectable lipolytics produce permanent, visible, and highly valued results. When any of these elements is wrong, the risk of adverse outcomes — prolonged swelling, irregular contour, nerve injury — increases substantially.
The category has matured considerably since the early days of lipodissolve — when heterogeneous, often unstandardised phosphatidylcholine formulations were administered with limited understanding of mechanism, dosing, or safety margins. The regulatory approval of deoxycholic acid (DCA) for submental fat reduction has brought pharmaceutical-grade evidence standards to the category, and Korean manufacturers have developed CE-marked lipolytic formulations that apply this science to a broader range of clinical applications.
This guide covers the complete clinical framework for injectable lipolytics: mechanism of action, the active agents used, clinical indications (and their limits), contraindications, injection protocol, combination strategies, and how to manage the post-treatment response. It is the pillar post for Celmade's Lipolytic content cluster. Browse Celmade's lipolytic range for current CE-marked Korean product availability.
What Are Lipolytic Injectables? Defining the Category
Lipolytic injectables are substances injected into subcutaneous adipose tissue that cause permanent destruction of adipocytes (fat cells) in the treated zone. This is categorically different from treatments that reduce fat through temperature (cryolipolysis), heat (laser lipolysis), or mechanical disruption (ultrasound cavitation) — lipolytics achieve adipocyte destruction through biochemical mechanisms.
The term 'lipolytic' is used somewhat loosely in aesthetics to encompass products that work through different specific mechanisms — true lipolysis (stimulation of the natural fat-releasing enzymatic pathway within the fat cell) is different from cytolytic mechanisms (physical destruction of the fat cell membrane). In practice, the two most clinically relevant active agents — deoxycholic acid and phosphatidylcholine — work primarily through membrane disruption (cytolytic) rather than true enzymatic lipolysis, though the clinical endpoint — permanent reduction of fat cells in the treated zone — is the same.
The Active Agents: DCA and Phosphatidylcholine
|
DEOXYCHOLIC ACID (DCA) — The Regulated Gold Standard |
|
What it is: A naturally occurring bile acid produced by the liver and secreted into the intestine, where it aids in the emulsification and absorption of dietary fats. When injected into subcutaneous fat, it acts as a detergent that disrupts the phospholipid bilayer of adipocyte cell membranes, causing permanent cell lysis. Regulatory status: FDA-approved (USA) and EMA-assessed for submental fat reduction under the brand name Kybella (USA) / Belkyra (EU). The first injectable lipolytic to achieve Class III medical device or pharmaceutical approval for aesthetic use. Mechanism: DCA's detergent properties cause non-selective cell membrane disruption. In the subcutaneous fat compartment, this results in adipocyte lysis with release of fat cell contents, triggering a local inflammatory response and subsequent macrophage clearance of the lysed cellular debris. The permanent adipocyte destruction is the basis of the durable clinical result. Clinical profile: The most extensively clinically validated lipolytic agent. DCA is non-selective — it destroys whatever cells it contacts, including non-adipocytes. This necessitates precise injection technique within the fat compartment. DCA-based products are available as pharmaceutical-grade formulations from CE-marked Korean manufacturers through Celmade's lipolytic range. Post-treatment response: Predictable and pronounced — significant swelling (oedema), erythema, and indurated (firm) tissue typically persist for 2–4 weeks as the inflammatory clearance response proceeds. Patients must be counselled extensively about this expected response. |
|
PHOSPHATIDYLCHOLINE (PC) — The Original Lipodissolve Agent |
|
What it is: A phospholipid that is a major structural component of biological cell membranes. When injected into subcutaneous fat in concentrations above physiological levels, it disrupts adipocyte membrane integrity and initiates cell death. Regulatory status: Not specifically approved for aesthetic fat reduction by the FDA, EMA, or MHRA. Used off-label in most markets. CE-marked Korean formulations are available that include PC as an active agent — CE marking covers the specific product formulation, not the individual agent. Mechanism: Less well-characterised than DCA at the cellular level. PC-based formulations typically also contain DCA (deoxycholate) as a solubiliser — and some evidence suggests that the DCA content, rather than the PC itself, is the primary lipolytic agent in many commercial PC formulations. The relative contribution of PC and DCA to the clinical effect in combined formulations remains debated in the literature. Clinical profile: PC/DCA combination formulations are widely used in international aesthetic practice, particularly for small-volume off-label applications. PC formulations are generally considered to produce a milder post-treatment inflammatory response than DCA-only formulations, though the evidence base for this difference is less robust. Korean formulations: Korean CE-marked lipolytic products available through Celmade typically combine PC and DCA in optimised ratios, drawing on extensive Korean clinical experience with these formulations across multiple indication types. |
Clinical Indications: Where Lipolytics Produce Reliable Results
Lipolytic injectables are not a solution for generalised adiposity — they are tools for targeted, localised reduction of specific subcutaneous fat deposits that are unresponsive to diet and exercise and that create a specific aesthetic concern. The following zones have the most established clinical evidence and practice experience:
|
Indication Zone |
Evidence Level |
Fat Characteristics |
Typical Volume Reduced |
Notes |
|
Submental fat ('double chin') |
Strong — multiple RCTs for DCA. Clinical standard. |
Submental fat pad — present in most anatomical studies as a defined compartment. Diet-resistant even in lean patients. |
1–3 sessions typically produce meaningful reduction. 4–6 sessions for complete clearance. |
The most evidence-supported application. DCA pharmaceutical approval specifically for this zone. Anatomy well-studied. Neurovascular structures understood and avoidable. |
|
Submandibular / jowl fat |
Moderate — clinical case series. Growing evidence. |
Superficial fat lateral to the jowl and along the mandibular border. |
Variable — depends on fat deposit volume. |
Technically more demanding than submental. Adjacent structures (marginal mandibular nerve) require precise technique. Experienced practitioners only. |
|
Infraorbital fat pads (lower eyelid 'bags') |
Limited and controversial — specialist application only. |
Orbital fat hernation through a weakened orbital septum. |
Very small volumes — high risk zone. |
Highly specialist application. Orbital fat hernation visible as eye bags may be addressable but the proximity of the orbit makes this a high-risk zone. Not recommended for general aesthetic practitioners. Surgical referral preferred for significant cases. |
|
Bra strap fat / axillary fold fat |
Moderate — clinical case series, extensive real-world use in Korean practice. |
Localised fat deposits at the bra strap line or axillary fold. |
1–3 sessions. |
Off-label application. Well-tolerated. Korean practitioners have extensive experience with this application. Good outcomes in motivated patients with localised deposit. |
|
Abdomen (localised deposits) |
Moderate — clinical experience. Limited RCT data. |
Localised fat deposits that persist despite appropriate diet and exercise. |
Multiple sessions required for larger volumes. |
Appropriate for small, localised fat deposits — not for generalised abdominal adiposity. Larger deposit = more sessions, more swelling, and diminishing predictability. |
|
Inner thighs |
Moderate — clinical experience. |
Localised fat deposit medial thigh. |
Multiple sessions. |
Effective for the right patient — small, localised deposits. High swelling volume post-treatment in this zone due to gravity-dependent oedema. |
|
Knee fat (medial) |
Moderate — clinical experience. |
Fat deposit medial to the knee creating fullness at the knee contour. |
1–3 sessions typically. |
A highly valued application — very diet-resistant fat deposit that patients find difficult to address. High patient satisfaction when appropriate patients are selected. |
What Lipolytics Cannot Do: Critical Scope Limitations
Setting the boundaries of lipolytic treatment capability is as important as describing what they can achieve — and is essential for both ethical consultation and satisfied patients:
• Lipolytics cannot replace weight loss. Injectable lipolytics destroy fat cells in the treated zone — they do not affect fat cells elsewhere in the body. A patient who is significantly overweight will not achieve meaningful body composition change from localised lipolytic treatment. They are tools for body contouring in patients at or near their target weight with specific, localised, diet-resistant fat deposits.
• Lipolytics cannot improve skin laxity. Fat cell destruction reduces fat volume. It does not tighten overlying skin. In patients with significant skin laxity, reduction of the fat volume beneath lax skin may make the laxity more visible rather than improving the overall appearance. Assess skin laxity before treating and consider whether fat reduction will improve or worsen the aesthetic outcome in the context of the skin quality.
• Lipolytics cannot treat visceral fat. Only subcutaneous fat — fat beneath the skin and above the muscle fascia — is accessible to injectable lipolytics. Visceral fat (intra-abdominal fat around organs) is not addressable with any injectable treatment.
• Lipolytics cannot produce immediate results. The therapeutic process — adipocyte lysis, inflammatory clearance, tissue remodelling — takes weeks. Patients will look worse before they look better. The full result of each session is not assessable for 6–8 weeks, and multiple sessions are typically required.
• Lipolytics are not appropriate for large-volume fat reduction. For significant fat reduction across large anatomical areas, surgical liposuction produces superior results with better contour predictability. Lipolytic injectables are best suited to small-to-medium localised deposits where the volume of fat is modest and the precision of injectable treatment is advantageous.
Contraindications and Precautions
Absolute Contraindications
• Active infection or inflammation at the proposed injection site
• Pregnancy and breastfeeding
• Known hypersensitivity to any component of the product formulation
• Active autoimmune conditions affecting the skin or connective tissue
• Current anticoagulant therapy at therapeutic dose (discuss with the prescribing physician)
• Dysphagia (difficulty swallowing) — specific contraindication for submental treatment due to risk of worsening swallowing difficulty if treatment effect extends to adjacent musculature
Relative Contraindications and Precautions
• Significant skin laxity overlying the proposed treatment zone: Fat reduction without skin tightening may worsen the aesthetic outcome. Discuss openly with patient before proceeding.
• Prior surgery in the treatment zone: Surgical scarring, altered anatomy, and disrupted tissue planes change the distribution of injectable products and may increase complication risk.
• Active acne or skin condition in the treatment zone: Injecting through inflamed skin increases infection risk.
• BMI above 30: Higher BMI patients have greater fat volume, greater post-treatment swelling, and less predictable contour outcomes. Select carefully and manage expectations explicitly.
• Thyroid or cervical lymph node pathology: For submental treatment specifically — confirm no thyroid pathology or lymphadenopathy in the treatment area before proceeding.
Injection Protocol: Submental Fat Reduction (Primary Application)
The submental zone is covered in detail here as the primary application with the strongest evidence base. Off-label body applications follow the same principles with adapted parameters.
Treatment Planning and Marking
Precise pre-injection marking is not optional — it is the primary safety measure for submental lipolytic treatment. The injection field must be defined within the anatomically safe zone:
• Superior border: 1–1.5cm below the inferior border of the mandible. The marginal mandibular nerve runs along or just below the mandibular border — staying more than 1cm below reduces the risk of nerve injury.
• Lateral borders: Medial to a vertical line dropped from the oral commissure on each side. Beyond this line, the neurovascular structures of the anterior neck become relevant.
• Inferior border: 1–1.5cm above the thyroid cartilage. The hyoid bone, cervical strap muscles, and anterior neck vessels all lie below this boundary.
• Midline: Mark the midline clearly. The injection grid should be symmetric around the midline.
Injection Grid and Parameters
Standard DCA-based submental protocol parameters:
• Needle gauge: 30G or 31G, 13mm length. Sufficient reach for the subcutaneous fat compartment in most patients.
• Injection angle: 90 degrees perpendicular to the skin surface. The needle is inserted straight down into the subcutaneous fat compartment.
• Injection depth: Into the subcutaneous fat — below the dermis, above the platysma muscle. In most patients this is 1–2cm below the skin surface at the submental zone. Always confirm you are in fat (soft, yielding tissue) and not in muscle (firm resistance).
• Volume per point: 0.2ml per injection point for DCA products. Some Korean formulations specify different volumes — always follow the product-specific protocol.
• Point spacing: 1cm grid across the marked treatment zone.
• Total injection points per session: Typically 20–50 points depending on the size of the fat deposit and the treatment zone. Total product volume per session: 4–10ml.
Step-by-Step Session Protocol
1. Photograph: Standardised frontal, oblique, and lateral photographs at rest and with chin extended. Essential for outcome comparison across sessions.
2. Mark the injection field: Mark all four boundaries of the safe treatment zone. Then mark the injection grid — 1cm spacing across the entire treatment zone. Count the points before starting.
3. Topical anaesthetic: Apply EMLA to the treatment zone 45–60 minutes before treatment. Ice can be applied immediately before injecting to augment anaesthesia.
4. Aspiration check (optional but recommended): Before injecting at each point, gently aspirate to confirm the needle tip is not in a blood vessel. Blood in the syringe indicates vascular placement — withdraw, apply pressure, and re-inject at an adjacent point.
5. Inject at each grid point: 0.2ml per point (or product-specific volume). Work systematically across the grid to ensure complete and even coverage.
6. Post-injection massage (product-specific): Some products benefit from gentle post-injection massage to distribute the product evenly across the treatment zone. Others should not be massaged to prevent product migration. Follow the product SPC.
7. Post-treatment ice: Apply ice pack to the treatment zone for 10–15 minutes immediately after completing all injections. Reduces immediate swelling and patient discomfort.
8. Document: Record: product used, batch number, number of injection points, volume per point, total volume, any adverse events noted during the session.
Treatment Protocol: Session Spacing and Assessment
|
Stage |
Timing |
Content |
Goal |
|
Consultation |
Before Session 1 |
Full assessment of submental fat and overlying skin laxity. Confirm indication vs contraindication. Photograph. Set realistic expectations regarding timeline, swelling, and number of sessions. |
Confirm appropriate patient and realistic expectation baseline. |
|
Session 1 |
Week 0 |
Standard protocol as above. Photograph at session start. |
Initiate adipocyte lysis. Begin the clearance process. |
|
Session 1 review |
Week 6–8 |
Assess treatment response. Photograph and compare with baseline. Determine whether further sessions are needed. |
The full effect of Session 1 requires 6–8 weeks to be assessable — significant swelling and induration will mask results earlier than this. Do not assess before week 6. |
|
Session 2 (if required) |
Week 6–8+ |
Same protocol as Session 1. The minimum interval between sessions is 4–6 weeks (manufacturer-dependent). Do not treat until post-treatment swelling from Session 1 has fully resolved. |
Continue fat reduction if the assessment shows residual fat requiring further treatment. |
|
Subsequent sessions |
Every 6–8 weeks minimum |
Continue until the desired result is achieved or the maximum number of sessions specified by the product (typically 4–6) is reached. |
Graduated fat reduction toward the patient's target contour. |
|
Final assessment |
8 weeks after last session |
Full photography comparison with baseline. Skin laxity reassessment. Combination treatment planning if needed. |
Objective documentation of final outcome. Plan skin tightening adjunct if laxity is apparent post-fat reduction. |
Managing the Post-Treatment Response
The post-treatment response to lipolytic injection is the most significant expectation management challenge in this treatment category. The inflammatory response to adipocyte lysis is pronounced — and patients who are not prepared for it interpret it as a complication rather than an expected part of the therapeutic process:
|
Time Post-Treatment |
Expected Response |
What to Tell the Patient |
|
0–4 hours |
Significant swelling develops rapidly. Erythema across the treatment zone. Burning and stinging sensation from the product. The area may feel hot to touch. |
'This is expected and normal. The swelling will be significant — please arrange to be at home for the rest of today and plan nothing important for 48–72 hours. Ice packs applied gently will help manage discomfort.' |
|
24–72 hours |
Swelling at its peak. The treated area may look significantly larger than before treatment. Hard, indurated texture from the acute inflammatory response. Bruising may be visible. |
'The swelling will peak in the first few days and will be at its worst at 48–72 hours. This means the treatment is working — the inflammatory response is clearing the destroyed fat cells. Do not be alarmed by how it looks at this stage.' |
|
Week 1–2 |
Swelling gradually reducing. Induration (firmness) beginning to soften. Erythema fading. The area may feel numb or slightly tender to touch. |
'You should notice the swelling beginning to reduce from around day 5–7. The area may feel firm and slightly numb — this is normal and will resolve. Do not assess the result at this stage — it's too early.' |
|
Week 3–4 |
Swelling largely resolved. Contour beginning to emerge. Some residual firmness may remain. |
'From around 3–4 weeks, you will begin to see the emerging result. The swelling is going and the fat reduction is becoming visible. But the full result takes 6–8 weeks — do not book a review before week 6.' |
|
Week 6–8 (review) |
Full effect of Session 1 assessable. Contour clearly improved. Skin may show some laxity now that fat volume is reduced — this should have been discussed at consultation. |
'This is where we assess the full result of your first session. Compare your photographs from session day 1 with today — the change should be clearly visible. We'll discuss whether a second session is appropriate based on what we see today.' |
|
The most important post-treatment instruction: Patients must be told before the first session — not after — that they will look significantly worse before they look better. A patient who has not been warned and who sees peak swelling at 48 hours will call the clinic in alarm and may present to A&E believing something has gone wrong. A patient who has been thoroughly counselled knows this is expected and will manage it calmly. There is no more important piece of pre-treatment communication in lipolytic practice. |
Korean Lipolytic Products: Clinical Standards and UK Availability
Korean aesthetic manufacturers have applied the same pharmaceutical manufacturing rigour to lipolytic products that has made Korean PDRN and HA skin boosters the global clinical standards in their categories. Korean CE-marked lipolytic formulations — available through Celmade's lipolytic range — are manufactured under MFDS pharmaceutical GMP standards and CE-marked for UK/EU distribution.
• DCA-based Korean formulations: Deoxycholic acid formulations at 1–2% concentration, the standard clinical range. Pharmaceutical-grade purity with batch certificates of analysis confirming DCA concentration, pH, osmolarity, and sterility.
• PC/DCA combination formulations: Phosphatidylcholine combined with deoxycholic acid in optimised ratios. Korean manufacturers have refined PC/DCA ratios based on extensive domestic clinical experience to produce formulations with predictable clinical responses and manageable post-treatment reactions.
• Concentration range: Korean lipolytic products are available in different DCA concentrations (1%, 1.25%, 2%) allowing practitioners to select appropriate intensity for the treatment zone — lower concentrations for sensitive or small-volume zones, standard concentrations for established applications.
• Documentation: As with all Celmade products, full documentation is supplied: CE certificate, MFDS manufacturer documentation, product SPC, batch CoA, and cold chain confirmation. See our Korean PDRN Products Selection Guide for the documentation framework — the same principles apply to lipolytic products.
Key Takeaways
• Injectable lipolytics permanently destroy adipocytes — through DCA's detergent membrane disruption or PC/DCA combination effects. The fat reduction is permanent in the treated zone.
• The submental zone is the primary, best-evidenced application — with pharmaceutical-grade DCA approval and multiple RCTs. Other zones (bra line, abdomen, inner thigh, medial knee) have growing evidence from clinical experience.
• Patient selection is the most critical factor — lipolytics treat localised, diet-resistant subcutaneous fat deposits in patients at or near healthy weight. They do not treat generalised obesity, visceral fat, or skin laxity.
• The post-treatment inflammatory response is pronounced and must be pre-communicated — peak swelling at 48–72 hours, full resolution at 3–4 weeks, result assessable at 6–8 weeks. Patients who are not warned will be alarmed.
• Precise injection technique and safe zone marking are non-negotiable — DCA destroys whatever cells it contacts. Incorrect placement (dermis, muscle, nerve proximity) produces predictable adverse outcomes.
• Korean CE-marked lipolytic formulations are the most accessible pharmaceutical-quality option — MFDS + CE dual approval, full documentation, 30–50% lower wholesale cost than European equivalents. Browse Celmade's lipolytic range.
Browse the full lipolytic collection at Celmade. For the broader injectable aesthetic context, see also: Complete Skin Boosters Guide and Complete Polynucleotides and PDRN Guide.
Frequently Asked Questions
Are injectable lipolytics the same as Kybella?
Kybella (USA) and Belkyra (EU) are the brand names for the FDA/EMA-approved pharmaceutical DCA product for submental fat reduction. Korean CE-marked DCA formulations use the same active agent (deoxycholic acid) at the same clinical concentrations and with the same mechanism of action. The Korean formulations do not carry the Kybella/Belkyra brand name but are manufactured under MFDS pharmaceutical GMP standards and CE-marked for European use. The clinical principle is identical — the product source is different.
How many sessions of lipolytic treatment are needed?
Most patients require 2–4 sessions for submental fat reduction, spaced 6–8 weeks apart. The number depends on the volume of fat present, the patient's individual inflammatory clearance response, and the result achieved after each session. Sessions should not be administered before week 6 post-previous session — the previous session's effect must be fully assessable before determining whether another session is needed. Some patients achieve their desired result after 1–2 sessions; others require the maximum of 4–6 sessions.
Is lipolytic treatment permanent?
The fat cells destroyed by lipolytic injection are permanently destroyed — they do not regenerate. In this sense, the treatment is permanent. However, remaining fat cells in the treated zone and adjacent zones can expand if the patient gains significant weight after treatment. Lipolytic treatment should be maintained in the context of a stable body weight — significant weight gain after treatment will reduce or negate the cosmetic result through expansion of remaining adipocytes.
What is the difference between lipolytic injectables and fat-freezing (cryolipolysis)?
Both treatments permanently destroy subcutaneous fat cells — but through completely different mechanisms. Cryolipolysis (e.g. CoolSculpting) applies controlled cold to the skin surface, freezing fat cells through an apoptotic mechanism without damaging overlying skin. Injectable lipolytics achieve adipocyte destruction biochemically through direct injection. Lipolytics can be used in zones too small or anatomically complex for cryolipolysis applicators (submental, medial knee, bra line). Cryolipolysis may be appropriate for larger, flat fat deposits where the applicator can be applied effectively. Neither is appropriate for generalised obesity.
Which body zones are safe for off-label lipolytic treatment?
Off-label lipolytic applications with established clinical experience include: bra-line/axillary fold fat, localised abdominal deposits, inner thigh fat, and medial knee. Each zone has specific injection field limits and anatomical landmarks that must be understood before treating. Zones with significant neurovascular proximity (jaw line, infraorbital) should only be treated by practitioners with advanced anatomical knowledge and specific training in those applications. Celmade's lipolytic range includes products appropriate for both submental and off-label body applications — confirm product-specific guidance with Celmade for each intended application.
